Register Login

SHATTUCK LABS, INC. (STTK)

SymbolSTTK
NameSHATTUCK LABS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address500 W. 5TH STREET,SUITE 1200, AUSTIN, Texas, 78701, United States
Telephone+1 512 900-4690
Fax—
Email—
Websitehttps://www.shattucklabs.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001680367
Description

Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.

Additional info from NASDAQ:
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.

2026-07-17 22:30

New Form SCHEDULE 13D/A - Shattuck Labs, Inc. <b>Filed:</b> 2026-07-17 <b>AccNo:</b> 0001104659-26-084768 <b>Size:</b> 17 KB

Read more
2026-07-07 23:00

Shukla Abhinav A. 🟡 adjusted position in 410 shares (2 derivative) of Shattuck Labs, Inc. (STTK) at $7.01 Transaction Date: Jul 02, 2026 | Filing ID: 297768

Read more
2026-07-03 00:17

Shukla Abhinav A. 🟡 adjusted position in 23.5K shares (2 derivative) of Shattuck Labs, Inc. (STTK) at $7.08 Transaction Date: Jun 30, 2026 | Filing ID: 295150

Read more
2026-07-03 00:15

Pandite Arundathy N. 🔴 sold 30.0K shares of Shattuck Labs, Inc. (STTK) at $7.01 Transaction Date: Jun 30, 2026 | Filing ID: 295148

Read more
2026-07-02 20:24

📋 Shukla Abhinav A. (Officer) plans to sell 410 shares of Shattuck Labs, Inc. (at $7.01 each, total $3K) Filed: Jul 02, 2026 | ID: 005072

Read more
2026-06-17 17:01

New Form SCHEDULE 13G - Shattuck Labs, Inc. <b>Filed:</b> 2026-06-17 <b>AccNo:</b> 0001172661-26-002457 <b>Size:</b> 11 KB

Read more
2026-06-15 22:13

Director Ashiya Mona 🟢 acquired 1.2M shares (2 derivative) of Shattuck Labs, Inc. (STTK) at $0.00 Transaction Date: Jun 11, 2026 | Filing ID: 000626

Read more
2026-06-15 22:12

Director ORBIMED ADVISORS LLC 🟢 acquired 1.2M shares (2 derivative) of Shattuck Labs, Inc. (STTK) at $0.00 Transaction Date: Jun 11, 2026 | Filing ID: 000625

Read more
2026-06-15 19:10

New Form SCHEDULE 13D/A - Shattuck Labs, Inc. <b>Filed:</b> 2026-06-15 <b>AccNo:</b> 0000947871-26-000624 <b>Size:</b> 32 KB

Read more
2026-06-11 22:00

New Form SCHEDULE 13D/A - Shattuck Labs, Inc. <b>Filed:</b> 2026-06-11 <b>AccNo:</b> 0001104659-26-073086 <b>Size:</b> 17 KB

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT07158437 Phase 1 Study of SL-325 in Healthy Volunteers Phase1 Healthy Volunteers Active_Not_Recruiting 2025-09-18 2026-07-01 ClinicalTrials.gov
NCT05483933 Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects … Phase1 Platinum-resistant Ovarian Cancer Completed 2022-08-18 2025-02-07 ClinicalTrials.gov
NCT05275439 Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML Phase1 Acute Myeloid Leukemia Terminated 2022-03-17 2025-02-06 ClinicalTrials.gov
NCT04502888 Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Ce… Phase1 Cutaneous Squamous Cell Carcinoma Terminated 2020-09-17 2022-04-08 ClinicalTrials.gov
NCT04406623 Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer Phase1 Ovarian Cancer Completed 2020-06-29 2023-02-02 ClinicalTrials.gov
NCT03894618 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Phase1 Squamous Cell Carcinoma of the Head and Neck Completed 2019-03-26 2023-05-04 ClinicalTrials.gov
Total clinical trials: 6
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
SL-172154 Other Phase PHASE1 Ovarian Cancer COMPLETED NCT04406623
Drug: SL-172154 Drug Phase PHASE1 Cutaneous Squamous Cell Carcinoma TERMINATED NCT04502888
SL-279252 Other Phase PHASE1 Squamous Cell Carcinoma of the Head and Neck COMPLETED NCT03894618
Mirvetuximab + SL-172154 Other Phase PHASE1 Platinum-resistant Ovarian Cancer COMPLETED NCT05483933
Pegylated Liposomal Doxorubicin + SL-172154 Other Phase PHASE1 Platinum-resistant Ovarian Cancer COMPLETED NCT05483933
Venetoclax Other Phase PHASE1 Acute Myeloid Leukemia TERMINATED NCT05275439
Azacitidine (AZA) Other Phase PHASE1 Acute Myeloid Leukemia TERMINATED NCT05275439
SL-172154 Other Phase PHASE1 Acute Myeloid Leukemia TERMINATED NCT05275439
Placebo (Normal Saline) Other Phase PHASE1 Healthy Volunteers ACTIVE_NOT_RECRUITING NCT07158437
SL-325 Other Phase PHASE1 Healthy Volunteers ACTIVE_NOT_RECRUITING NCT07158437
Placebo (Normal Saline) Other Phase PHASE1 Healthy Volunteers ACTIVE_NOT_RECRUITING NCT07158437
SL-325 Other Phase PHASE1 Healthy Volunteers ACTIVE_NOT_RECRUITING NCT07158437
Placebo (Normal Saline) Other Phase PHASE1 Healthy Volunteers ACTIVE_NOT_RECRUITING NCT07158437
SL-325 Other Phase PHASE1 Healthy Volunteers ACTIVE_NOT_RECRUITING NCT07158437
Placebo (Normal Saline) Other Phase PHASE1 Healthy Volunteers ACTIVE_NOT_RECRUITING NCT07158437
SL-325 Other Phase PHASE1 Healthy Volunteers ACTIVE_NOT_RECRUITING NCT07158437
Placebo (Normal Saline) Other Phase PHASE1 Healthy Volunteers ACTIVE_NOT_RECRUITING NCT07158437
SL-325 Other Phase PHASE1 Healthy Volunteers ACTIVE_NOT_RECRUITING NCT07158437
Placebo (Normal Saline) Other Phase PHASE1 Healthy Volunteers ACTIVE_NOT_RECRUITING NCT07158437
SL-325 Other Phase PHASE1 Healthy Volunteers ACTIVE_NOT_RECRUITING NCT07158437
Placebo (Normal Saline) Other Phase PHASE1 Healthy Volunteers ACTIVE_NOT_RECRUITING NCT07158437
SL-325 Other Phase PHASE1 Healthy Volunteers ACTIVE_NOT_RECRUITING NCT07158437
Placebo (Normal Saline) OTHER Phase PHASE1 Healthy Volunteers RECRUITING NCT07158437
SL-325 BIOLOGICAL Phase PHASE1 Healthy Volunteers RECRUITING NCT07158437
Mirvetuximab + SL-172154 DRUG Phase PHASE1 Platinum-resistant Ovarian Cancer COMPLETED NCT05483933
Pegylated Liposomal Doxorubicin + SL-172154 DRUG Phase PHASE1 Platinum-resistant Ovarian Cancer COMPLETED NCT05483933
Venetoclax DRUG Phase PHASE1 Acute Myeloid Leukemia TERMINATED NCT05275439
Azacitidine (AZA) DRUG Phase PHASE1 Acute Myeloid Leukemia TERMINATED NCT05275439
Drug: SL-172154 DRUG Phase PHASE1 Cutaneous Squamous Cell Carcinoma TERMINATED NCT04502888
SL-172154 DRUG Phase PHASE1 Acute Myeloid Leukemia TERMINATED NCT05275439
SL-279252 DRUG Phase PHASE1 Squamous Cell Carcinoma of the Head and Neck COMPLETED NCT03894618
Total products: 31